Aim To evaluate the concordance between data derived from randomized controlled trial (RCT) and real-world estimates of HbA 1c and weight change after 24 weeks of initiation of a basal-bolus compared with a premixed insulin regimen in people with Type 2 diabetes.
Introduction
Insulin therapy is essential for people with Type 2 diabetes when diet and other glucose-lowering therapy options have failed to achieve optimum HbA 1c targets [1] in order to reduce the risks of long-term vascular complications [2, 3] . Although basal-bolus and premixed insulin are the two most widely used insulin regimens in Type 2 diabetes, there is no overall consensus regarding the most effective or optimum insulin regimen [4, 5] . The basal-bolus regimen, which consists of multiple daily injections of rapid-acting insulin preprandially in addition to a long-acting basal insulin, most closely mimics the pattern of insulin secretion [6] , but the flexibility of this regimen is undermined by its complexity; daily carbohydrate intake must be counted and the insulin dose adjusted accordingly [7] [8] [9] . The premixed insulin regimen consists of a fixed ratio of rapid-acting insulin and intermediate insulin combined, thereby eliminating the need Correspondence to: Iskandar Idris. E-mail: Iskandar.Idris@nottingham.ac.uk for patients to mix or adjust the insulin themselves, whilst also reducing the number of required daily injections. Although patients may find it easier to adhere to the premixed regimen [10] , regular meal times and consistency in daily routine are sometimes necessary in order to gain maximum benefit and avoid the associated risk of hypoglycaemia.
Randomized controlled trials (RCTs) and meta-analyses have shown heterogeneous outcomes between basal-bolus and premixed insulin regimens [11] [12] [13] ; therefore, the choice of the optimum insulin regimen continues to be debated [14] . Although RCTs meet regulatory and scientific standards, they do not necessarily reflect what happens in real-world settings [15] . The use of trial-derived estimates of clinical outcomes, when used to underpin guidelines, may present a biased view of the relative outcomes of treatments when used in routine practice. Failing to account for this discrepancy may lead to suboptimal patient outcomes and wasted healthcare resources.
The aim of the present study, therefore, was to evaluate the concordance between data derived from RCTs and realworld estimates of HbA 1c and weight reduction at 24 weeks after initiation of a basal-bolus compared with a premixed insulin regimen and to assess their inter-relationship between clinical characteristics and relevant clinical profiles as determinants of concordance.
Methods

Study design and data sources
Data were extracted from two sources: (1) observational data from UK primary care obtained from The Health Improvement Network (THIN) and (2) RCTs in people with Type 2 diabetes.
The search strategy and terms used in the systematic selection of these trials have been fully described in our previous study [16] ; however, we added an additional exclusion criterion in which trials lasting <6 months were excluded. The eight RCTs selected [11, 12, [17] [18] [19] [20] [21] [22] had randomized, double-bind parallel or crossover designs in which a basal-bolus insulin regimen was compared with a premixed insulin regimen.
In the observational (real-world) population, we pooled data from THIN on people with Type 2 diabetes who initiated insulin therapy (either basal-bolus or premix). THIN contains the UK computerized anonymized longitudinal primary care records, with details of >10.5 million patients derived from 532 general practices within the UK that have been shown to be demographically representative of the dynamics of the UK population [23] . We have previously published diabetes-related outcomes in routine clinical practice using this database [24, 25] .
Exposures and outcomes
In both the real-world and RCT populations, the main exposure was an insulin regimen: basal-bolus vs premixed. The premixed (biphasic) regimen intervention was defined as two or more injections of any brand of premixed insulin per day, while the basal-bolus regimen was defined as any basal injection with at least a single bolus injection per day. These were specified in detail in the treatment protocols of the RCTs, while in the real-world data, these prescriptions were identified by their appropriate READ codes in THIN. The main outcomes were mean differences in glycaemic control (measured by HbA 1c ) and weight between the two populations, measured at ≥6 months.
Covariates
For both populations (RCT and real-world), data on baseline demographics and patients' characteristics were obtained. In addition, baseline and 6-month measurements of HbA 1c and body weight were obtained. Other important clinical measures, such as comorbidity status, medication use and other biochemical variables, were obtained in the real-world population.
Statistical analyses
For both the RCT and real-world data, the difference between HbA 1c at baseline and at 6 months (glycaemic control) was computed. The difference in weight at baseline and at 6 months was also computed. Generally, descriptive statistics were used to summarize the baseline variables in both population groups. Missing data among the baseline covariates in the real-world data were accounted for with multiple imputations using the chained equation model. Student's t-test was used to determine the mean differences in HbA 1c and weight between the insulin regimens at baseline and after 24 weeks. Linear regression analyses were conducted to identify What's new?
• Although evidence from randomized controlled trials (RCTs) suggests that basal-bolus insulin regimens are effective, their effectiveness in real-world practice remains unclear.
• This study is the first to evaluate the concordance between data derived from RCTs and real-world estimates of HbA 1c and weight in basal-bolus compared with premixed insulin regimens, and to assess their inter-relationship with patient-related and relevant clinical characteristics, as determinants of concordance.
• This study highlights specific discrepancies in HbA 1c reduction and weight change between real-world outcomes and RCT results. Greater baseline weight was associated with a more favourable effect on weight outcome after a premixed than after a basal-bolus insulin regimen. 
Results
Baseline characteristics
There were a total of 21 637 participants, with 3410 in the RCT and 18 227 in the real-world populations. Of these, 9376 people were treated with a basal-bolus insulin regimen, while 12 261 were on the premixed insulin regimen.
In the real-world (THIN) population, the overall mean (SD) age was 61.5 (13.8) years, with a mean baseline HbA 1c of 72 mmol/mol (8.7%) in the premixed insulin group vs 72 mmol/mol (8.7%) in the basal-bolus insulin group and a mean baseline weight of 90.7 kg in the premixed insulin group vs 92.1 kg in the basal-bolus insulin group. Other important baseline variables in this group are summarized in Table 1 . Weight, age, diastolic blood pressure and comorbidity status differed significantly between the two regimens at baseline. In the RCT population [9, 10, [15] [16] [17] [18] [19] [20] , the mean HbA 1c and weight were 74 mmol/mol (8.9%) vs 74 mmol/ mol (8.9%) and 85.6 kg vs 85.6 kg, respectively, in participants on the basal-bolus vs premixed insulin regimens. Other important baseline variables are summarized in Table 2 [11, 12, [17] [18] [19] [20] [21] [22] .
Change in HbA 1c
Data from THIN (real-world population) showed there was a significant reduction from the baseline HbA 1c of 70 mmol/ mol (8.6%) to 67 mmol/mol (8.3%) after 6 months (mean difference 0.28%, 95% CI -0.30 to -0.27; P < 0.0001). Both the premixed and basal-bolus insulin regimens led to similar reductions at 6 months. There was better glycaemic control in the basal-bolus arm at 6 months of insulin initiation (mean difference -0.08%, 95% CI -0.11 to -0.04; P = 0.0001 [ Fig. 1a]) .
Similarly, the RCT population showed a significant improvement in glycaemic control, with a mean reduction in HbA 1c of 1.4% (95% CI -1.87 to -0.92; P<0.0001) at 6 months from baseline. There was a significant reduction in HbA 1c at 6 months [74 mmol/mol (8.9%) to 58 mmol/mol (7.5%); mean difference 1.34%, 95% CI -2.09 to -0.6; P = 0.003] in the premixed insulin group, as well as in the basalbolus insulin group [74 mmol/mol (8.9%) to 57 mmol/mol (7.4%); mean difference 1.44%, 95% CI -2.20 to -0.69; P = 0.0023]. No significant difference in glycaemic control was observed between the two insulin regimens after adjustment for age and baseline weight.
Change in weight
Overall, there was a significant increase in weight after 6 months in the real-world population (mean difference 0.27, 95% CI 0.18 to 0.35; P < 0.0001), with an increase of 0.31 kg (95% CI 0.20, 0.42; P < 0.0001) in the premixed insulin arm vs 0.21 kg (95% CI 0.07, 0.34; P = 0.002) in the basalbolus arm. Nonetheless, no significant difference in weight gain was recorded between these two (premixed vs basalbolus) regimens at 6 months (Fig. 1b) .
In the RCT population overall, there was significant increase in weight from 88.9 kg at baseline to 91.9 kg at 6 months (mean difference 2.96 kg, 95% CI 2.05 to 3.88; P < 0.0001). In the premixed insulin arm, there was an increase in weight from 88.9 to 91.2 kg (mean difference 2.26 kg, 95% CI 0.80, 3.71; P = 0.009), while the basal-bolus arm there was a greater increase of 88.8 to 92.6 kg (mean difference 3.67 kg, 95% CI 2.43 to 4.92; P = 0.0004), but the difference between the changes recorded at 6 months in the two arms (2.26 vs 3.67 kg) was not significant.
Predictors of response at baseline
In the real-world population (derived from THIN), there was a weak correlation between baseline HbA 1c and response to treatment (change in HbA 1c ) because 20% of the variability in the change in HbA 1c in this group was attributable to the HbA 1c at baseline (r 2 = 0.20; slope = À0.30; 95% CI À0.31
to À0.2; P< 0.0001). There was a very little correlation attributable to age (slope = À0.004; P< 0.001), gender (slope = À0.05; P = 0.019), and duration of diabetes (slope = À0.003; P = 0.031). By contrast, in the RCT population, there was a strong correlation between baseline HbA 1c and change in HbA 1c . A total of 88% of this variability in change in HbA 1c was attributable to the HbA 1c at baseline (r 2 = 0.88; slope = À1.43; 95% CI À1.77 to À1.08; P < 0.0001).
There was a non-significant correlation with age (slope = 0.04; P=0.941) and weight (slope = À0.02; P = 0.069).
HbA 1c reduction as a function of baseline HbA 1c in the premixed and basal-bolus insulin regimens Figure 2 shows the comparison between the two insulin regimens in the real-world and RCT populations. These showed similar patterns of response to treatment as a function of baseline HbA 1c ; i.e. there was a greater response to treatment with higher baseline HbA 1c values but this was steeper in the RCT population for both regimens. At baseline HbA 1c levels of 64 mmol/mol (8.0%) and 62 mmol/mol (7.8%), both populations showed no change in HbA 1c at 6 months, but below these levels, both populations showed an increase in HbA 1c value at 6 months, this increase also being Weight change as a function of baseline weight in the premixed and basal-bolus insulin regimens
For changes in weight according to baseline weight, different response patterns were observed between the two insulin regimens (Fig. 3) in the RCT population. In the real-world population, there was a weak correlation between baseline weight and weight after 6 months. A total of 2% of the variability in weight change was attributable to the weight at baseline (r 2 = 0.02; slope = À0.049; 95% CI À0.05 to À0.04; P < 0.0001). This was independent of gender, age and duration of diabetes. In the RCT population, there was a slightly higher non-significant correlation between baseline weight and weight change at 6 months, as 49% of the variability in weight change was attributable to weight at baseline (r 2 = 0.49; slope = 0.06; 95% CI À0.04 to 0.15;
P=0.204), independent of age (slope = 0.07; P = 0.74). The premixed insulin regimen showed a slight negative correlation in the real-world population between weight at baseline and change in weight at 6 months of insulin initiation (r 2 =0.03; slope = À0.05; 95% CI À0.06 to À0.04; P < 0.0001), i.e. those with a baseline weight of >100 kg experienced weight reduction, while those weighing <100 kg at baseline experienced weight gain at 6 months ( Fig. 2a) , but in the RCT population, this association was almost constant (r 2 = 0.0005; slope = À0.003; 95% CI À0.17 to 0.16; P = 0.962), meaning that there was no change in weight at 6 months, irrespective of baseline weight. For the basal-bolus regimen, the real-world population showed a weak negative correlation (r 2 = 0.02; slope = À0.05; 95% CI À0.05 to À0.04; P < 0.0001); i.e. there was a slight weight reduction as baseline weight increased. Conversely, the RCT group showed a positive correlation (r 2 = 0.45; slope = 0.09; 95% CI À0.02, À0.19; P = 0.098); i.e. there was more weight gain at 6 months as baseline weight increased. Taken together, at any baseline weight >60 kg, while the RCT population showed a weight gain, the real-world population had a slight reduction in weight.
HbA 1c change as a function of baseline weight in the premixed and basal-bolus insulin regimen
The change in HbA 1c as a function of baseline weight for the premixed and basal-bolus insulin regimens showed that for both the real-world and RCT populations, greater baseline weight was associated with reduced response to treatment. The association was much steeper, however, for the RCT compared with the real-world population. Furthermore, for the premixed insulin regimen, for any baseline weight, response to treatment was greater in the RCT population N, total number of all trial participants in these trials; NR, not reported. Diabetes duration is the duration of diabetes as at the commencement of the trial.
compared with the real-world population up to the weight of 110 kg, above which response to treatment was greater for the real-world population. Similarly, for the basal-bolus insulin regimen, for any baseline weight, response to treatment was greater in the RCT population than in the real-world population up to the weight of~110 kg, above which response to treatment became greater in the real-world population.
Discussion
In the present analysis we compared the relative HbA 1c and weight outcomes of premixed insulin regimens or basal-bolus insulin regimens in people with Type 2 diabetes in RCTs and real-world conditions. Despite the significant difference in HbA 1c found between basal-bolus and premixed insulin (a) (b) FIGURE 3 Graphs showing change in weight as a function of baseline weight (kg) in type 2 diabetes population on insulin therapy after ≥24 weeks.
Comparison is made between the real-world (data from The Health Improvement Network) and the randomized controlled trial (RCT) populations in people on (a) a premixed and (b) a basal-bolus insulin regimen. Interaction coefficients: (a) À0.049, P<0.0001 and (b) 0.06, P=0.204).
ª 2017 Diabetes UK regimens in the real-world population in the present study, the clinical relevance of this is unclear and no difference in HbA 1c or weight was noted between insulin regimens in either the real-world or the RCT populations at 6 months. A discordance in the pattern of treatment response was observed, however, between the populations for both insulin regimens. While the present analysis confirms the expected relationship between baseline HbA 1c and HbA 1c reduction with either a premixed or a basal-bolus insulin regimen, the strength of this relationship was considerably more apparent in the RCT compared with the real-world population. We observed a negative association between weight change at 6 months and baseline weight among people receiving a premixed insulin regimen in both the real-world and RCT populations, i.e. as baseline weight increased, the weights in these populations at 6 months slightly reduced, and this was more marked in the real-world population. For people receiving a basal-bolus insulin regimen, however, a discordance in response was observed between the real-world and RCT populations, i.e. there was a negative association (a reduction in weight at 6 months as baseline weight increased) in the real-world population, but a positive association (an increase in weight at 6 months as baseline weight increased) in the RCT population. Lastly, for both premixed and basalbolus insulin regimens, the expected relationship between baseline weight and response to insulin treatment was most apparent in the RCT population.
The reason for the discrepancies in the HbA 1c and weight response with premixed insulin or a basal-bolus insulin regimen in the real-world population compared with the RCT population is not clear; however, initiation of an insulin regimen is associated with hypoglycaemia and weight gain [26, 27] , with the latter often occurring only during the first months after insulin initiation, and an important difference between the premixed and the basal-bolus insulin regimen is that the latter can be more demanding because of increased frequency of insulin injections and dose adjustments.
It is tempting to speculate that any discrepancies between real-world and RCT data are caused by fear of hypoglycaemia (especially among people on a basal-bolus insulin regimen [26] ), weight gain [27] , reduced adherence to a basal-bolus insulin regimen or patients' ambivalent attitudes to uptitrating insulin doses in real-world conditions because of lack of monitoring, patient education or rigid guidelines or protocols for patients to follow [28] . Fear of hypoglycaemia in real-world settings, for example, may explain the less apparent association between baseline HbA 1c and response to treatment in the real-world compared with the RCT population for both insulin regimens. Other possible explanations include the younger age of the RCT population and the higher rate of comorbidities and selection bias in the realworld population.
Our observation that greater baseline weight was associated with more favourable effect on weight outcome with premixed insulin therapy and to a lesser extent with basalbolus insulin regimen should provide important reassurance that, in routine clinical practice, meaningful reductions in HbA 1c can be achieved without significant detrimental effect on weight. This observation was supported by findings from two other studies [29, 30] . In their study involving 155 917 patients who had recently initiated insulin therapy, Paul et al. [29] reported that obese patients gain significantly less weight with insulin and that progressive reduction in body weight gain was observed with progressive increases in baseline BMI >30 kg/m 2 , thought to be attributable to the use of less intensive insulin therapy. Another study reported a significant inverse association of baseline BMI with weight gain in a cohort of 2179 people with a median diabetes duration of~9 years [30] . Interestingly, the converse relationship between baseline weight and weight change was observed in our RCT cohort who received the basal-bolus, but not the premixed insulin regimen. This implies an increased propensity to weight gain with a basal-bolus insulin regimen compared with a premixed insulin regimen in an RCT setting, supported by our findings from a systematic review and meta-analysis comparing basal-bolus and the premixed insulin [31, 32] . In addition, the 4-T study reported that mean weight gain was higher in the prandial group than in either the biphasic group or the basal group [31] .
The present analysis is subject to some limitations inherent to observational studies, including potential confounders such as adherence to therapy, indication bias, ethnicity and differences in insulin regimens or titration protocols used across different areas in the UK. We attempted to minimize these by restricting the analysis only to people who initiated a specific insulin regimen. Importantly, we do not have robust information on hypoglycaemic events that may limit the success of a given therapy, patient education programmes, the use and frequency of glucose self-monitoring, the frequency of insulin dose adjustment and rules for selfadjustment of insulin dose or adjustment by feeling, which have all been shown to be important confounders [8, 31, 33] . With regard to the analysis of the RCT data, our previous meta-analysis in this area showed substantial heterogeneity in HbA 1c change. This may be attributed to a number of confounding factors, such as poor study quality, small treatment groups, short study duration and different study designs. Lastly, we pooled trials and real-world data using regular and analogue insulin because previous meta-analysis suggests similar HbA 1c outcomes between the two types [28] . Despite these limitations, it is important to note that the emphasis of the present study is a pragmatic approach to decision-making for initiation of insulin among patients who require insulin soon after diagnosis of diabetes in 'real-world' clinical practice based on variables that are available to clinicians, and to compare this with outcomes (glycaemic control and change in weight) derived from RCTs. This is because clinical trials involve strict adherence to treatment based on randomization to a given insulin regimen while, in the real world, the choice of insulin regimen involves the patient and takes other clinical and metabolic concerns into consideration. Additionally, unlike in RCTs which have a tight time schedule, treatment in real-world settings is not limited by time. This confers an 'advantage' to participants of RCTs over those in real-world situations because people with diabetes need to deal with an insulin regimen not only for 6 to 12 months as in RCTs, but for a long, often life-long, time.
In summary, the present study shows a discordance in the pattern and magnitude of treatment response in real-world and RCT populations between the two insulin regimens. The 'blunting' of the expected relationship between baseline HbA 1c and the response to treatment with either a premixed or a basal-bolus insulin regimen in the real world, and the reverse association between weight change and baseline weight among people receiving the two insulin regimens between real-world and RCT populations, emphasized the importance of patient-related factors that would determine the potential success of one insulin regimen compared with another. Choice of insulin regimen should therefore be individualized according to patients' personal, social and clinical characteristics.
